Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
IN8bio (NASDAQ:INAB) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $(0.14) by 57.14 percent. This is a 31.25 percent increase over losses of $(0.32) per share from the same period last year.
Posted In: INAB